Equities research analysts forecast that ASLAN PHARMACEU/ADR (NASDAQ:ASLN) will post ($0.16) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for ASLAN PHARMACEU/ADR’s earnings. The lowest EPS estimate is ($0.17) and the highest is ($0.15). ASLAN PHARMACEU/ADR posted earnings per share of ($0.35) in the same quarter last year, which suggests a positive year over year growth rate of 54.3%. The company is expected to issue its next earnings results on Friday, March 27th.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.
According to Zacks, analysts expect that ASLAN PHARMACEU/ADR will report full-year earnings of ($0.69) per share for the current financial year, with EPS estimates ranging from ($0.70) to ($0.68). For the next year, analysts expect that the firm will report earnings of ($0.71) per share, with EPS estimates ranging from ($0.80) to ($0.53). Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that follow ASLAN PHARMACEU/ADR.
ASLAN PHARMACEU/ADR (NASDAQ:ASLN) last issued its earnings results on Tuesday, August 13th. The company reported ($0.25) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.20) by ($0.05).
A number of research analysts recently commented on the company. Zacks Investment Research raised ASLAN PHARMACEU/ADR from a “hold” rating to a “strong-buy” rating and set a $2.00 price target on the stock in a report on Monday, November 4th. ValuEngine raised ASLAN PHARMACEU/ADR from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Finally, Piper Jaffray Companies set a $7.00 price target on ASLAN PHARMACEU/ADR and gave the stock a “buy” rating in a report on Monday, September 30th.
A hedge fund recently raised its stake in ASLAN PHARMACEU/ADR stock. FNY Investment Advisers LLC grew its position in ASLAN PHARMACEU/ADR (NASDAQ:ASLN) by 57.8% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 19,100 shares of the company’s stock after acquiring an additional 6,993 shares during the quarter. FNY Investment Advisers LLC owned 0.06% of ASLAN PHARMACEU/ADR worth $33,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 7.18% of the stock is owned by institutional investors and hedge funds.
NASDAQ:ASLN traded down $0.05 during trading hours on Friday, hitting $2.08. The stock had a trading volume of 13,900 shares, compared to its average volume of 19,259. The business’s 50 day moving average is $1.71 and its 200-day moving average is $2.73. The company has a debt-to-equity ratio of 1.12, a quick ratio of 3.80 and a current ratio of 1.88. ASLAN PHARMACEU/ADR has a one year low of $1.46 and a one year high of $6.48. The company has a market cap of $56.41 million, a price-to-earnings ratio of -1.49 and a beta of 2.40.
About ASLAN PHARMACEU/ADR
ASLAN Pharmaceuticals Limited, a clinical-stage oncology-focused biopharmaceutical company, engages in the development of drugs for prevalent cancers. It targets diseases that are prevalent in Asia, and orphan indications in the United States and Europe. The company's lead program, varlitinib, is a reversible small molecule pan-human epidermal growth factor receptor, or pan-HER, inhibitor that targets the human epidermal growth factor receptors HER1, HER2, and HER4.
Read More: Marijuana Stocks Future Looks Bright
For more information about research offerings from Zacks Investment Research, visit Zacks.com